Ras-PI3K Pathway in Nf1-/-Hematopoiesis and Leukemia
Ras-PI3K Pathway in Nf1-/-Hematopoiesis and Leukemia
批准号:
7192516
负责人:
DAVID A INGRAM
金额:
$6.37万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-27 至 2007-06-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Neurofibromatosis type 1 (NF1) is a genetic disorder caused by mutations in the NF1 tumor suppressor gene. Children with NF1 are predisposed to developing juvenile myelomonocytic leukemia (JMML). Neurofibromin, the protein product of NF1, is a negative regulator of p21ras activity. Though Nf1 -/- mice die in utero, mice reconstituted with Nf1 -/- fetal stem cells develop a myeloproliferative disease (MPD) similar to JMML in NF1 patients. However, alterations in p21ras signaling pathways in NF1 deficient cells responsible for MPD are unknown. Utilizing PI-3 kinase (PI3K) inhibitors, we have preliminary data implicating hyperactivation of the p21ras-PI3K pathway as responsible for the hyperproliferation and increased survival of Nf1 -/- cells. However, interpretation of results using PI3K inhibitors is limited because there are four classes of PI3K, and inhibitors inactivate all classes. Here we propose genetic experiments to determine whether hyperactivation of class IAPI3K alters the growth of Nf1 -/- hematopoietic cells. Our rationale for studying class IAPI3K in Nf1-/- cells is twofold. First, in contrast to other PI3Ks, all class IAPI3K catalytic subunits contain a p21ras-binding domain. Second, p21ras interacts with these subunits to augment kinase activity in vitro, and no evidence exists to show that p21ras augments the activity of other PI3K classes. Recently, a p85alpha (a regulatory subunit of class IAPI3K) knockout strain was generated which results in a 97% reduction in class IAPI3K activity in myeloid cells. We hypothesize that hyperactivation of the p21ras-class IAPI3K pathway, alters the proliferation and survival of Nf1 -/- hematopoietic cells and contributes to the progression of MPD in mice transplanted with Nf1 -/- cells. To test this hypothesis, we will conduct experiments utilizing a genetic intercross of Nf1 +/- and p85alpha knockout mice. The aims are: 1) To test whether hyperactivation of class IAPI3K contributes to MPD in mice reconstituted with Nf1 -/- stem cells by altering specific signaling pathways, 2) To examine how genetic inactivation of class IAPI3K alters the proliferation and survival of committed, multipotential, and primitive Nf1 +/+ and Nf1 -/- progenitor cells, 3) To examine how neurofibromin and class IAPI3K regulate cell cycle progression and survival of phenotypically defined hematopoietic cells in vivo.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
RESPONSE TO LETTER TO THE EDITOR - "Critical assessment of putative endothelial progenitor phenotypes" by Gian Paolo Fadini, et al.
回复给编辑的信 - Gian Paolo Fadini 等人的“推定内皮祖细胞表型的批判性评估”。
DOI:
10.1016/j.exphem.2007.07.014
发表时间:
2007
期刊:
Experimental hematology
影响因子:
2.6
作者:
[Case,Jamie, Haneline,LauraS, Yoder,MervinC, Ingram,DavidA]
通讯作者:
Ingram,DavidA
Molecular Dissecfion of NF1 Vasoocclusive and Aneurysm Disease
-
批准号:8700545
-
项目类别:
-
资助金额:$37.38万
-
财政年份:2005
-
负责人:DAVID A INGRAM
-
依托单位:
Molecular Dissecfion of NF1 Vasoocclusive and Aneurysm Disease
-
批准号:8015868
-
项目类别:
-
资助金额:$33.84万
-
财政年份:2005
-
负责人:DAVID A INGRAM
-
依托单位:
Molecular Dissecfion of NF1 Vasoocclusive and Aneurysm Disease
-
批准号:8381830
-
项目类别:
-
资助金额:$36.22万
-
财政年份:2005
-
负责人:DAVID A INGRAM
-
依托单位:
NF Center: From Animal Models to Therapeutics
-
批准号:7000897
-
项目类别:
-
资助金额:$20.89万
-
财政年份:2005
-
负责人:DAVID A INGRAM
-
依托单位:
Molecular Dissecfion of NF1 Vasoocclusive and Aneurysm Disease
-
批准号:8328652
-
项目类别:
-
资助金额:$36.32万
-
财政年份:2005
-
负责人:DAVID A INGRAM
-
依托单位:
Molecular Dissecfion of NF1 Vasoocclusive and Aneurysm Disease
-
批准号:8533030
-
项目类别:
-
资助金额:$35.68万
-
财政年份:2005
-
负责人:DAVID A INGRAM
-
依托单位:
Ras-PI3K Pathway in Nf1-/-Hematopoiesis and Leukemia
-
批准号:6866481
-
项目类别:
-
资助金额:$12.74万
-
财政年份:2002
-
负责人:DAVID A INGRAM
-
依托单位:
Ras-PI3K Pathway in Nf1-/-Hematopoiesis and Leukemia
-
批准号:7038203
-
项目类别:
-
资助金额:$12.74万
-
财政年份:2002
-
负责人:DAVID A INGRAM
-
依托单位:
Ras-PI3K Pathway in Nf1-/-Hematopoiesis and Leukemia
-
批准号:6506645
-
项目类别:
-
资助金额:$6.51万
-
财政年份:2002
-
负责人:DAVID A INGRAM
-
依托单位:
Ras-PI3K Pathway in Nf1-/-Hematopoiesis and Leukemia
-
批准号:6666753
-
项目类别:
-
资助金额:$12.8万
-
财政年份:2002
-
负责人:DAVID A INGRAM
-
依托单位:
Ras-PI3K Pathway in Nf1-/-Hematopoiesis and Leukemia
-
批准号:6738006
-
项目类别:
-
资助金额:$12.74万
-
财政年份:2002
-
负责人:DAVID A INGRAM
-
依托单位:
NF Center: From Animal Models to Therapeutics
-
批准号:7557436
-
项目类别:
-
资助金额:$20.28万
-
财政年份:--
-
负责人:DAVID A INGRAM
-
依托单位:
NF Center: From Animal Models to Therapeutics
-
批准号:7678398
-
项目类别:
-
资助金额:$21.29万
-
财政年份:--
-
负责人:DAVID A INGRAM
-
依托单位:
NF Center: From Animal Models to Therapeutics
-
批准号:7557442
-
项目类别:
-
资助金额:$21.76万
-
财政年份:--
-
负责人:DAVID A INGRAM
-
依托单位:
NF Center: From Animal Models to Therapeutics
-
批准号:7911628
-
项目类别:
-
资助金额:$21.81万
-
财政年份:--
-
负责人:DAVID A INGRAM
-
依托单位:
国内基金
海外基金
登录
查看更多内容
力学响应干细胞外囊泡通过Sclerostin/PI3K/AKT轴促进骨腱界面损伤愈合的作用机制研究
-
批准号:2026JJ50337
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:肖汉
-
依托单位:
基于“痞积转化”理论探究网果酸模通过PI3K/Akt通路调控巨噬细胞极化平衡抑制胃癌的分子机制
-
批准号:JCZRLH202601927
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
葛根素通过调控PI3K/Akt介导的代谢重编程抑制心肌梗死后心脏纤维化的机制研究
-
批准号:2026JJ80327
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:张婷
-
依托单位:
基于PI3K/Akt信号通路探索气道炎症在慢性阻塞性肺疾病中的作用及培元固肺膏干预研究
-
批准号:2026JJ82022
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:刘丹
-
依托单位:
基于PI3K/Akt信号通路探讨钩大青酮调控BGN-COL1A1轴抑制结肠癌侵袭与迁移的机制研究
-
批准号:2026JJ82464
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:陆文洪
-
依托单位:
成纤维细胞中NR2F1-AS1协同KRAS通过PI3K/AKT/mTOR途径促进胰腺导管腺癌发展
-
批准号:2026JJ82537
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:周小兵
-
依托单位:
基于PI3K/Akt/mTOR信号通路介导的细胞自噬探讨参芪通痹胶囊治疗虚瘀证糖尿病周围神经病变的作用机制研究
-
批准号:2026JJ81891
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:潘娟
-
依托单位:
CSTA通过PI3K/AKT/mTOR通路调控角质形成细胞自噬-凋亡平衡在糖尿病足溃疡复发中的作用及机制研究
-
批准号:2026JJ81911
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:许云华
-
依托单位:
金荞麦黄酮靶向抑制c-MET介导的PI3K/Akt和Ras/MAPK通路逆转NSCLC EGFR-TKI耐药的机制研究
-
批准号:2026JJ81256
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:李弘德
-
依托单位:
“补肾健脾,化痰通络”法调控PI3K/Akt/MCT1介导的乳酸转运改善血管性痴呆的机制研究
-
批准号:JCZRLH202600974
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位: